WO2024243428A3 - Use of fusion constructs for cell therapy - Google Patents

Use of fusion constructs for cell therapy Download PDF

Info

Publication number
WO2024243428A3
WO2024243428A3 PCT/US2024/030816 US2024030816W WO2024243428A3 WO 2024243428 A3 WO2024243428 A3 WO 2024243428A3 US 2024030816 W US2024030816 W US 2024030816W WO 2024243428 A3 WO2024243428 A3 WO 2024243428A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell therapy
fusion constructs
constructs
endogenous
vivo
Prior art date
Application number
PCT/US2024/030816
Other languages
French (fr)
Other versions
WO2024243428A2 (en
Inventor
Robert Hawkins
Original Assignee
Instil Bio Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instil Bio Inc. filed Critical Instil Bio Inc.
Publication of WO2024243428A2 publication Critical patent/WO2024243428A2/en
Publication of WO2024243428A3 publication Critical patent/WO2024243428A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K40/4255—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4264—Cancer antigens from embryonic or fetal origin
    • A61K40/4266—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/55—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Provided herein are methods employing various fusion constructs in T cell therapy. The fusion constructs can be co-administered with endogenous IL-2 and without IL-2 in other embodiments in an vivo T cell therapy.
PCT/US2024/030816 2023-05-24 2024-05-23 Use of fusion constructs for cell therapy WO2024243428A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363504156P 2023-05-24 2023-05-24
US63/504,156 2023-05-24

Publications (2)

Publication Number Publication Date
WO2024243428A2 WO2024243428A2 (en) 2024-11-28
WO2024243428A3 true WO2024243428A3 (en) 2025-01-16

Family

ID=93590461

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/030816 WO2024243428A2 (en) 2023-05-24 2024-05-23 Use of fusion constructs for cell therapy

Country Status (1)

Country Link
WO (1) WO2024243428A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160346326A1 (en) * 2015-05-28 2016-12-01 Kite Pharma, Inc. Methods of Conditioning Patients for T Cell Therapy
US20220112263A1 (en) * 2015-09-04 2022-04-14 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160346326A1 (en) * 2015-05-28 2016-12-01 Kite Pharma, Inc. Methods of Conditioning Patients for T Cell Therapy
US20220112263A1 (en) * 2015-09-04 2022-04-14 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of use

Also Published As

Publication number Publication date
WO2024243428A2 (en) 2024-11-28

Similar Documents

Publication Publication Date Title
MX2021002415A (en) Genetically engineered hematopoietic stem cells and uses thereof.
WO2005028626A3 (en) Cell culture media
WO2023004282A3 (en) Il12 receptor agonists and methods of use thereof
MX2022005774A (en) Targeted integration at alpha-globin locus in human hematopoietic stem and progenitor cells.
WO2023164671A3 (en) Compositions and methods for epigenome editing to enhance t cell therapy
PH12022550543A1 (en) Universal donor cells
WO2023018990A3 (en) Lipids for nucleic acid delivery
SA522432641B1 (en) T composition for regulatory cell culture and use
IT1317835B1 (en) MODIFIED CYTOKINES FOR USE IN CANCER THERAPY.
WO2022235622A3 (en) Cd20 targeting fusion proteins and methods of use thereof
WO2021178833A3 (en) Designed il-2 variants
TWD207860S (en) Electrical interface of battery pack
WO2024243428A3 (en) Use of fusion constructs for cell therapy
WO2023126943A3 (en) Additive manufacturing of dental prostheses
WO2023230534A3 (en) Use of fusion constructs for il-2 independent t cell therapy
ZA201907623B (en) T cells with reduced surface fucosylation and methods of making and using the same
WO2023159136A3 (en) Epitope engineering of cell-surface receptors
WO2022256546A3 (en) Gene editing in primary immune cells using cell penetrating crispr-cas system
WO2024049979A3 (en) Novel ionizable lipids and lipid nanoparticles and methods of using the same
DE60327710D1 (en) MODIFIED CYTOKINS FOR CANCER THERAPY
WO2023245108A3 (en) Compositions and methods for reducing mhc class i in a cell
MX2020011757A (en) Gene therapy methods and compositions using auxotrophic regulatable cells.
WO2021203058A3 (en) Combination therapy involving anti-cd39 antibodies and adoptive cell therapy
WO2007044648A3 (en) Oncohumouse
WO2023086572A3 (en) Combinations of nanoparticle-encapsulated cargo entities and methods for making and using same